Membranous nephropathy
Conditions
Interventions
Observation group:None
Sponsors
The Second People’s Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily participate in the study and sign the informed consent form; 2. Aged >=18 years, regardless of gender; 3. Membranous nephropathy (MN) confirmed by renal biopsy; 4. Estimated glomerular filtration rate (eGFR) > 40 ml/min; 5. Received rituximab treatment; 6. Expected survival time >= 12 months;
Exclusion criteria
Exclusion criteria: 1. Secondary nephrotic syndrome; 2. Treatment with immunosuppressants (e.g., tacrolimus, cyclosporine, cyclophosphamide, etc.); 3. Complicated with infectious diseases such as hepatitis B, hepatitis C, and HIV; 4. Hypersensitivity to rituximab or murine proteins; 5. Complicated with severe active infection; 6. Patients with severe impairment of immune response (e.g., hypogammaglobulinemia, significant reduction in CD4 or CD8 cell counts); 7. Complicated with severe heart failure (NYHA Class ?); 8. Complicated with malignant tumors (e.g., prostate cancer, breast cancer, renal cell carcinoma, etc.); 9. Pregnancy, lactation, or use of unreliable contraceptive methods.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete or partial proteinuria remission rate at 12 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete or partial proteinuria remission rate at 6 months;Treatment non-response rate at 6 and 12 months;Either a 50% increase in eGFR from baseline or progression to ESRD;Complete remission rate at June and December;Immunological response index, protein and renal function index; | — |
Countries
China
Contacts
Public ContactYu Yi
The Second People’s Hospital of Shenzhen
Outcome results
None listed